Unranked

Bright Minds Biosciences Inc.

DRUG

$74.61

-1.98% (24h)

Last updated: 1 second ago

Market Cap

$732.08M

Volume (24h)

205.3K

Last Close (7D)

$74.61

View on TradingView

Earnings Aug 13 · in 23d

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

26

Website

brightmindsbio.com

Country

🇺🇸 United States

A Vancouver-based clinical-stage biotech designing next-generation serotonin-targeting drugs for serious psychiatric disorders — aiming to deliver psychedelic-like therapeutic benefits without the hallucinogenic experience.

🧪 Precision serotonin agonists designed to achieve therapeutic efficacy without causing full hallucinogenic effects
🧠 Pipeline targets treatment-resistant depression, epilepsy, PTSD, and addiction — conditions with massive unmet need
🔬 Differentiated chemistry positions Bright Minds for broader patient acceptance than classical psychedelics face

Key Stats

52-Week Range

$25.77$123.75

Beta0.10

Trailing P/EN/A

Forward P/E-8.66

Trailing EPS-2.41

Avg Volume316.79K

Enterprise Value$422.47M

Shares Outstanding9.81M

Earnings & Analyst

Next Earnings2026-08-13

EPS Estimate-1.64

Target Mean Price$166.93

RecommendationNone

Recommendation MeanN/A